India Pharma Outlook Team | Monday, 25 May 2026
India emerges as a major pillar for Novo Nordisk’s global drug development and launch strategy, with its Bengaluru center now playing a critical role across clinical, regulatory and commercial functions.
From analyzing trial data to preparing regulatory submissions, a significant share of global launch activity is being executed out of India.
John Dawber, Managing Director - Global Business Services, Novo Nordisk, noted, “a good proportion of the work for any market (launch) would be done out of the India center… there’s probably not a medicine launched anywhere… without a thumbprint of Bangalore.”
This growing centrality reflects not just operational scale but a deeper integration of India into Novo’s global innovation ecosystem, particularly as the company builds a more digitally driven, AI-enabled model for drug development.
Building on this India-led execution model, Novo Nordisk is aggressively deploying artificial intelligence to compress drug development timelines. The company aims to reduce the time between final clinical trial completion and regulatory filing by up to two-thirds.
Dawber highlighted the shift, stating that historically this phase took around 18 months, but with AI, “we’re able to… bring that time down by months.”
AI is now embedded across critical processes, including drafting regulatory documents, analyzing safety data, and enabling commercial analytics. This aligns with a broader pharmaceutical industry trend where machine learning is expected to significantly reduce early-stage development timelines over the next few years.
Novo’s approach goes further by tightly integrating AI with its global delivery centers, particularly in India, creating a more agile and scalable development model.
While operational transformation is underway, Novo Nordisk is simultaneously strengthening its position in the obesity drug market through improved clinical outcomes.
Recent data for its higher-dose Wegovy injection showed weight loss of up to 27.7 percent among early responders, with overall averages nearing 21 percent, compared to over 17 percent at earlier doses. These figures bring its efficacy closer to Eli Lilly’s Zepbound, which has set a high benchmark in the segment.
In parallel, Novo has expanded its portfolio with the launch of an oral obesity pill in the U.S., with India playing a key role in supporting its global rollout. However, competitive intensity and pricing pressures continue to test the company’s market share, particularly as rivals scale rapidly.
Taken together, Novo Nordisk’s strategy reflects a three-pronged approach: India-led execution, AI-driven acceleration and data-backed product competitiveness. Its success will depend on how effectively it can align these elements to regain leadership in the fast-evolving obesity therapeutics market.
Novo Nordisk is a global pharmaceutical company headquartered in Denmark, specializing in diabetes care, obesity treatments, and chronic disease therapies, known for innovations like insulin and GLP-1 drugs, with a growing focus on AI-driven drug development.
.jpg)
.jpg)
